JPRN-UMIN000009083已完成2 期
Phase II study of S-1, leucovorin plus bevacizumab in refractory colorectal cancer - Phase II study of S-1, leucovorin plus bevacizumab in refractory colorectal cancer
Aichi Cancer Center Hospital, Department of Clinical Oncology0 个研究点目标入组 30 人开始时间: 2012年10月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Patient with symptomatic brain metastases (2) Massive pleural or paricardial effusion, ascites that required drainage (3) Severe proteinuria (4) Severe comorbidity (5) Pregnant or possibly pregnant, and nursing women (6) Other conditions not suitable for this study
研究者
相似试验
已完成
2 期
Phase II study of S-1 plus Bevacizumab combination chemotherapy for patients with non-small-cell lung cancer.lung cancerJPRN-UMIN000004677Shinshu University thoracic surgery55
未知
2 期
A Randomized Phase II Study of S-1 plus Leucovorin versus S-1 alone in Patients with Gemcitabine-Refractory Advanced Pancreatic Cancer.Pancreatic cancerJPRN-jRCT2080221515Taiho Pharmaceutical Co., Ltd.140
已完成
2 期
Study PDX-LVRelapsed/Refractory peripheral T-cell lymphoma(r/r PTCL)JPRN-jRCT2080224048MUNDIPHARMA K.K.13
已完成
2 期
Phase II study of oral S-1 plus oral leucovorin in patients with previously treated non-small-cell lung cancerPre-treated non-small cell lung cancerJPRN-UMIN000004568Protocol team for S-1 with leucovorin therapy32
已完成
2 期
Phase II study of Bevacizumab with SOX (S-1 plus L-OHP) as second-line therapy in metastatic colorectal cancerMetastatic colorectal cancerJPRN-UMIN000005199Tsuchiura kyodo general hospital33